Shares of Kadmon Holdings (KDMN) have lost a third of their value since I wrote my ASH update piece last year. In the article, I noted that new clinical results from a mid-stage study evaluating Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor KD025 in patients with chronic graft-versus-host disease (cGVHD) demonstrated impressive response rates and durability.
In my June update piece, I viewed the $113.2 million secondary offering as a positive development given that a portion of the financing went directly to institutional investors who wanted to get in or add to their